 | | PRD_000618 | | Name: | (1S,7S)-7-amino-7-benzyl-N-[(1S)-4-carbamimidamido-1-{(1S)-1-hydroxy-2-oxo-2-[(2-phenylethyl)amino]ethyl}butyl]-8-oxohexahydro-1H-pyrazolo[1,2-a]pyridazine-1-carboxamide | | Formula: | C30 H42 N8 O4 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000619 | | Name: | (1S,7S)-7-amino-7-benzyl-N-{(1S)-4-carbamimidamido-1-[(S)-hydroxy(1,3-thiazol-2-yl)methyl]butyl}-8-oxohexahydro-1H-pyra
zolo[1,2-a]pyridazine-1-carboxamide | | Formula: | C24 H34 N8 O3 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000621 | | Name: | D-phenylalanyl-N-{(1S)-1-[(S)-1,3-benzothiazol-2-yl(hydroxy)methyl]-4-carbamimidamidobutyl}-L-prolinamide | | Formula: | C27 H35 N7 O3 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000622 | | Name: | amino{[(4S)-4-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)-5-oxo-5-{(2R)-2-[3-oxo-3-(1,3-thiazol-2-yl)propyl]pip
eridin-1-yl}pentyl]amino}methaniminium | | Formula: | C29 H40 N7 O4 S2 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000623 | | Name: | N-methyl-D-phenylalanyl-N-{(1S)-4-carbamimidamido-1-[(6-carboxy-1,3-benzothiazol-2-yl)carbonyl]butyl}-L-prolinamide | | Formula: | C29 H35 N7 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000632 | | Name: | (1R,2S,3R,1S',1S")Phosphoric acid mono(4-{2-[1-(1,2-dicarbamoylethylcarbamoyl)-3-carbamoylpropylcarbamoyl]-3-methylcarbamoylcyclopropyl}phenyl) ester | | Formula: | C22 H32 N5 O9 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000655 | | Name: | N-[(2R,4S)-4-hydroxy-2-(2-methylpropyl)-4-oxido-7-oxo-9-phenyl-3,8-dioxa-6-aza-4-phosphanonan-1-oyl]-L-leucine | | Formula: | C21 H33 N2 O8 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000656 | | Name: | N-[(S)-[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]-L-leucyl-L-alanine | | Formula: | C25 H34 N3 O7 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000657 | | Name: | methyl N-[(2S)-2-({(S)-hydroxy[(1R)-3-methyl-1-{[N-(3-methylbutanoyl)-L-valyl-L-valyl]amino}butyl]phosphoryl}oxy)-3-phenylpropanoyl]-L-alanyl-L-alaninate | | Formula: | C36 H60 N5 O10 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000659 | | Name: | N-(3-methylbutanoyl)-L-valyl-N-{(1S)-1-[(R)-[(1R)-1-benzyl-2-methoxy-2-oxoethoxy](hydroxy)phosphoryl]-3-methylbutyl}-L-
valinamide | | Formula: | C30 H50 N3 O8 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000664 | | Name: | N-(3-methylbutanoyl)-L-valyl-N-{(1R)-1-[(R)-(2-ethoxy-2-oxoethyl)(hydroxy)phosphoryl]-3-methylbutyl}-L-valinamide | | Formula: | C24 H46 N3 O7 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000667 | | Name: | (2S)-N-[[2-(aminomethyl)-5-chloro-phenyl]methyl]-1-[(2R)-5-carbamimidamido-2-(phenylmethylsulfonylamino)pentanoyl]pyrrolidine-2-carboxamide | | Formula: | C26 H36 Cl N7 O4 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000668 | | Name: | N~2~-{(2S)-3-[(R)-hydroxy{(1R)-2-phenyl-1-[(phenylacetyl)amino]ethyl}phosphoryl]-2-methylpropanoyl}-L-lysyl-D-serine | | Formula: | C29 H41 N4 O8 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000669 | | Name: | 1-{3-[(R)-{(1R)-1-[(glycyl-L-prolyl)amino]-2-phenylethyl}(hydroxy)phosphoryl]propanoyl}-L-prolyl-D-norleucine | | Formula: | C29 H44 N5 O8 P | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000693 | | Name: | (PHQ)LPA(B27) PEPTIDE | | Formula: | C26 H40 N4 O6 S | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000696 | | Name: | PSEUDOTYROSTATIN | | Formula: | C23 H28 N2 O5 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000701 | | Name: | TYROSTATIN | | Formula: | C29 H39 N3 O6 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000705 | | Name: | MICROGININ FR1 | | Formula: | C38 H57 N5 O9 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000708 | | Name: | AIAF, ACE ILE ALA PHA | | Formula: | C20 H31 N3 O4 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000720 | | Name: | BACILLOMYCIN L-3 | | Formula: | C35 H50 N10 O16 | | Description: | BACILLOMYCIN ANALOGUE IS A CYCLIC HEPTA-LIPOPEPTIDE
WITH 8 AMINO-ACIDS OF CONFIGURATION LLDDLLDL
THE BETA-ALANINE IS LINKED VIA A PEPTIDE BOND
TO BOTH RESIDUES 2 AND 8. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000723 | | Name: | PYOVERDIN C-E Fe Complex | | Formula: | C55 H82 Fe N17 O22 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000724 | | Name: | PYOVERDIN 18-1 Fe Complex | | Formula: | C57 H84 Fe N17 O24 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000725 | | Name: | PYOVERDIN R Fe Complex | | Formula: | C48 H64 Fe N15 O21 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000726 | | Name: | PYOVERDIN 13525 Fe Complex | | Formula: | C49 H71 Fe N14 O19 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000728 | | Name: | Synthetic PYOVERDINE Fe Complex | | Formula: | C56 H81 Fe N17 O24 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
